glp 1 for kidney disease GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic Potential kidney-protective and other effects
Description
retrospective analysis of 886 patients found retained gastric contents in 24.2% of semaglutide patients versus 5.1% of controls (adjusted odds ratio 5.15, 95% confidence interval 1.9212.92), yet actual aspiration occurred in only 1 of 404 patients (0.24%) [31]
When you look past consumer packaged goods (CPG), the impact of GLP-1 drugs is less easy to predict but arguably even more disruptive
In contrast to the requirement that Byetta be taken 60 minutes before meals, your colleagues know that Victoza can be taken without regards to meals and only one time a day
doi: 10.1007/s00018-010-0398-3 126 MacQueenG.FrodlT
